Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

616 Articles

Chris Lange | May 12, 2015 at 9:50 AM EDT

Short Sellers Keep Strong Bets Against Big Pharma

The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Lee Jackson | May 6, 2015 at 10:00 AM EDT

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the…

Chris Lange | May 5, 2015 at 10:50 AM EDT

Top Credit Suisse Major Pharma Stock Picks to Buy

Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.

Lee Jackson | Apr 22, 2015 at 8:30 AM EDT

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

A new report from Deutsche Bank highlights all of the known risks and focuses in on stocks that are reasonable…

Lee Jackson | Apr 20, 2015 at 9:10 AM EDT

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising…

Lee Jackson | Mar 16, 2015 at 8:55 AM EDT

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason…

Lee Jackson | Mar 6, 2015 at 8:20 AM EST

The Next 3 Likely Biotech Buyout Candidates

Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics…

Chris Lange | Mar 5, 2015 at 10:40 AM EST

Just How Expensive Is the Pharmacyclics Buyout?

News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21…

Chris Lange | Feb 23, 2015 at 4:45 PM EST

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings…

Lee Jackson | Feb 23, 2015 at 9:05 AM EST

Jefferies 4 Top Pharmaceutical Stocks to Buy

One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks…

Chris Lange | Feb 18, 2015 at 8:50 AM EST

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.

Jon C. Ogg | Feb 9, 2015 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.

Lee Jackson | Feb 5, 2015 at 10:00 AM EST

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the…

Chris Lange | Feb 3, 2015 at 12:20 PM EST

What to Expect From Gilead Earnings

Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.

Chris Lange | Jan 30, 2015 at 8:55 AM EST

Are Humira Sales Enough to Lift AbbVie?

AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.

1 … 36 37 38 39 40 … 42

AbbVie : ABBV

All AbbVie Articles

Short Sellers Keep Strong Bets Against Big Pharma

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Top Credit Suisse Major Pharma Stock Picks to Buy

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

The Next 3 Likely Biotech Buyout Candidates

Just How Expensive Is the Pharmacyclics Buyout?

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

Jefferies 4 Top Pharmaceutical Stocks to Buy

Neurocrine Biosciences Announces New Offering

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

What to Expect From Gilead Earnings

Are Humira Sales Enough to Lift AbbVie?

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

SpaceX Just Erased $1 Trillion in Value. Here’s Why the Worst Could Be Yet to Come.

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

AbbVie : ABBV

All AbbVie Articles

Short Sellers Keep Strong Bets Against Big Pharma

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Top Credit Suisse Major Pharma Stock Picks to Buy

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

The Next 3 Likely Biotech Buyout Candidates

Just How Expensive Is the Pharmacyclics Buyout?

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

Jefferies 4 Top Pharmaceutical Stocks to Buy

Neurocrine Biosciences Announces New Offering

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

What to Expect From Gilead Earnings

Are Humira Sales Enough to Lift AbbVie?

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

SpaceX Just Erased $1 Trillion in Value. Here’s Why the Worst Could Be Yet to Come.

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account